Skip to main content
OpenTrials

Clinical trial condition

Histiocytosis

Explore clinical trials studying Histiocytosis. Study availability and eligibility vary by location and protocol.

396 public trials 79 recruiting studies
Refine in advanced search Browse all conditions

Histiocytosis trial results

Active, Not Recruiting

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904

Conditions
Hemic and Lymphatic Diseases, Histiocytosis, Histiocytosis, Langerhans-Cell, +5 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Children's Hospital of Los Angeles Los Angeles, California, United States
  • University of California San Francisco Medical Center San Francisco, California, United States
View all 15 locations
View Trial Details
Active, Not Recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

NCT03213704

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994

Conditions
Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 107 locations
View Trial Details
Active, Not Recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04320888

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 174 locations
View Trial Details
Active, Not Recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 116 locations
View Trial Details
Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Conditions
DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, +21 more
Locations
  • Loma Linda University Cancer Center Loma Linda, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Advent Health Orlando Orlando, Florida, United States
  • Indiana University Indianapolis, Indiana, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

NCT04551131

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hemophagocytic Lymphohistiocytosis, +7 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Children's Hospital of Orange County Orange, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Children's National Medical Center Washington D.C., District of Columbia, United States
View all 13 locations
View Trial Details

Related conditions